Haseeb Ahmad appointed as Novartis Pharmaceuticals UK Ltd. Managing Director UK & Ireland and Country President UK
Feb 15, 2017
• Haseeb Ahmad appointed as Managing Director UK & Ireland for Novartis Pharmaceuticals UK Ltd. and Country President UK • Mr Ahmad will be a member of the Novartis European Executive Committee (EEC)
Frimley, February 15th, 2017 – Novartis Pharmaceuticals UK Ltd. (Novartis UK) announced today the appointment of Haseeb Ahmad as Managing Director UK & Ireland for the Pharmaceuticals business and Country President UK.
Mr Ahmad joins Novartis UK from Merck Sharp & Dohme (MSD) where he was Managing Director for MSD Greece, Cyprus and Malta. He brings almost 20 years of experience in the industry at a multi-country and global level, including more than 13 years based in the UK.
“I am immensely proud to join the Novartis UK team. As a market, the UK is very important. It is at the forefront of healthcare reform and through partnership with the NHS, Novartis can deliver important medicines and innovative solutions for patients,” explains Mr Ahmad. “As a company, I have greatly admired Novartis and am thrilled to accept this role. Novartis has a rich history and heritage, life changing medicines and an exciting pipeline. But most importantly, Novartis lives by its strong values to do business and deliver for patients in the right way.”
Marie-France Tschudin, Head Novartis Pharmaceuticals, Region Europe, adds: “I am delighted that Haseeb has joined Novartis to lead our UK Pharmaceuticals business as Managing Director and as Country President for the UK. I look forward to working with Haseeb and to the continued success of the UK & Ireland teams.”
About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.
In the UK, Novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes. Based on four sites across the north and south of England, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis by manufacturing the active pharmaceutical ingredients used worldwide in many medicines. In 2015 Novartis in the UK invested over £50million in R&D and is the largest commercial sponsor of clinical trials. For more information, please visit www.novartis.co.uk.